| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/20/2001 | EP1107774A1 Ramp2a: receptor activity modifying protein-2a |
| 06/20/2001 | EP1107768A1 STABLE HYPOXIA INDUCIBLE FACTOR-1 alpha AND METHOD OF USE |
| 06/20/2001 | EP1107702A1 Ultrasonic enhancement of drug injection |
| 06/20/2001 | EP1071485A4 Revascularization apparatus having coaxial channeling and injection means |
| 06/20/2001 | CN1300323A Recombinant (alpha)-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| 06/20/2001 | CN1300294A Frameshift mutants of beta-amyloid precursor protein and ubiquitin-B and their use |
| 06/20/2001 | CN1299868A Construction and use of recombinant herpes simplex virus |
| 06/19/2001 | US6248867 Polypeptide associated with proper eye function; for the diagnosis of vision defects |
| 06/19/2001 | US6248723 Method for treatment of inflammatory disease |
| 06/19/2001 | US6248722 Topically administering a dosage of an expression vector containing hepatocyte growth factor (hgf) gene; gene therapy with reduced side effects |
| 06/19/2001 | US6248720 Method for gene therapy using nucleic acid loaded polymeric microparticles |
| 06/19/2001 | US6248594 Kinesin-like motor protein |
| 06/19/2001 | US6248587 Contacting cells with angiotensin/angiotensinogen derivative of specific amino acid sequence |
| 06/19/2001 | US6248576 Histidinol dehydrogenase |
| 06/19/2001 | US6248565 Immunization with plasmid encoding immunogenic proteins and intracellular targeting sequences |
| 06/19/2001 | US6248557 RatC |
| 06/19/2001 | US6248556 Nucleotide sequence of guanosine triphosphate-binding protein from staphylococcus; diagnosis of infections; drug screening; bactericides; bacteriostats; vaccines; probes; primers; vectors; host cells |
| 06/19/2001 | US6248555 Nucleotide and amino acid sequence of mutant presenilin 1; diagnosis; screening; drug screening; probes; primers; host cells; vectors |
| 06/19/2001 | US6248527 Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E |
| 06/19/2001 | US6248517 Amino acid sequences; diagnosis of lyme disease; recombinant production; vaccines |
| 06/19/2001 | US6248351 Prevent transforming phenotype |
| 06/19/2001 | US6248326 Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor |
| 06/19/2001 | US6248320 Herpes simplex virus; genetic engineering |
| 06/14/2001 | WO2001042506A1 T1 receptor-like ligand ii and uses thereof |
| 06/14/2001 | WO2001042487A2 Device for extraction of nucleic acids |
| 06/14/2001 | WO2001042484A1 Il-6 like polynucleotide |
| 06/14/2001 | WO2001042481A2 Canine adenovirus vectors for the transfer of genes into target cells |
| 06/14/2001 | WO2001042472A2 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE |
| 06/14/2001 | WO2001042471A2 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | WO2001042466A2 Zvwf1: a member of the von willebrand factor type a domain superfamily |
| 06/14/2001 | WO2001042465A2 Chordin-like molecules and uses thereof |
| 06/14/2001 | WO2001042464A2 Human preoptic regulatory factor-2 and uses thereof |
| 06/14/2001 | WO2001042461A2 Apoptin-associating protein |
| 06/14/2001 | WO2001042459A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 06/14/2001 | WO2001042457A2 Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses |
| 06/14/2001 | WO2001042449A2 Methods for introducing genes into mammalian subjects |
| 06/14/2001 | WO2001042445A2 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS |
| 06/14/2001 | WO2001042444A2 Methods for expression of genes in primates |
| 06/14/2001 | WO2001042443A1 Method for modifying genetic characteristics of an organism |
| 06/14/2001 | WO2001042442A2 Activation of endogenous genes by genomic introduction of a replicon |
| 06/14/2001 | WO2001042437A2 Histone deacetylase-8 proteins, nucleic acids, and methods of use |
| 06/14/2001 | WO2001042424A2 Sphingolipid-containing cationic liposomes for topical delivery of bioactive material |
| 06/14/2001 | WO2001042305A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001042304A1 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 06/14/2001 | WO2001042302A1 HUMAN PROTEIN AND cDNA |
| 06/14/2001 | WO2001042301A1 Interferon-alpha induced gene |
| 06/14/2001 | WO2001042297A2 Clasp-3 transmembrane protein |
| 06/14/2001 | WO2001042296A2 Clasp-5 transmembrane protein |
| 06/14/2001 | WO2001042295A2 Clasp-7 transmembrane protein |
| 06/14/2001 | WO2001042288A2 G-protein coupled receptors |
| 06/14/2001 | WO2001042266A1 Antisense modulation of amyloid beta protein expression |
| 06/14/2001 | WO2001041814A1 Method of administering adenovirus |
| 06/14/2001 | WO2001041813A2 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 06/14/2001 | WO2001041810A2 Nucleic acid delivery system |
| 06/14/2001 | WO2001041804A1 Modulation and assay of fx activity in cells in cancer, inflammatory responses and diseases and in autoimmunity |
| 06/14/2001 | WO2001041792A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001041739A2 Liposomes |
| 06/14/2001 | WO2001041704A2 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | WO2001041674A1 Medical device |
| 06/14/2001 | WO2001017537A3 Methods and compositions for reducing immune response |
| 06/14/2001 | WO2001016168A3 Induction of programmed cell death by n5 gene |
| 06/14/2001 | WO2001009189A3 Compositions and methods for the treatment of tumors |
| 06/14/2001 | WO2001000829A8 Human endogenous retrovirus in breast cancer |
| 06/14/2001 | WO2000078358A3 Hyaluronic acid microspheres for sustained gene transfer |
| 06/14/2001 | WO2000032631A3 Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof |
| 06/14/2001 | US20010003585 Introducing a viral expression vector having a tumoricidal or susceptibility gene into a mammalian cell and attaching the cell to a support matrix in vitro; transferring the supported cells to mammalian tumor cells; durability; brains |
| 06/14/2001 | CA2395417A1 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 06/14/2001 | CA2394917A1 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | CA2394303A1 Interferon-alpha induced gene |
| 06/14/2001 | CA2394099A1 Adenovirus vectors for the transfer of genes in targeted cells |
| 06/14/2001 | CA2393859A1 Apoptin-associating protein |
| 06/14/2001 | CA2393725A1 Histone deacetylase-8 proteins, nucleic acids, and methods of use |
| 06/14/2001 | CA2393661A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393532A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393526A1 Nucleic acid delivery system |
| 06/14/2001 | CA2393469A1 Method of administering adenovirus |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2392742A1 T1 receptor-like ligand ii and uses thereof |
| 06/14/2001 | CA2392740A1 Il-6 like polynucleotides, polypeptides, and antibodies |
| 06/14/2001 | CA2392568A1 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | CA2392299A1 Methods for expression of genes in primates |
| 06/14/2001 | CA2391944A1 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 06/14/2001 | CA2390354A1 Device for extraction of nucleic acids |
| 06/14/2001 | CA2383001A1 Methods for introducing genes into mammalian subjects |
| 06/14/2001 | CA2362685A1 Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens |
| 06/13/2001 | EP1106692A1 Rna virus vector having contact infiltration capability |
| 06/13/2001 | EP1106185A1 Method of administering adenovirus |
| 06/13/2001 | EP1105738A1 Assays, methods and means for modulating nuclear localisation |
| 06/13/2001 | EP1105538A2 HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS |
| 06/13/2001 | EP1105518A1 USE OF mCRP FOR DELIVERY OF MATERIALS INTO CELLS |
| 06/13/2001 | EP1105513A2 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 06/13/2001 | EP1105506A1 Adenoviral vectors encoding erythropoietin and their use in gene therapy |
| 06/13/2001 | EP1105503A2 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGCALPHA1/BETA1) |
| 06/13/2001 | EP1105488A2 $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF |
| 06/13/2001 | EP1105483A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 06/13/2001 | EP1105476A1 Pharmaceutical composition for treating or preventing diabetes or cancer, or the waardenburg syndrome |
| 06/13/2001 | EP1105465A1 NOVEL G PROTEIN-COUPLED RECEPTOR cDNA SEQUENCE |
| 06/13/2001 | EP1105464A1 Human mesencephalon cell lines and methods of use therefor |
| 06/13/2001 | EP1105463A1 Cell population containing non-fetal hemangioblasts and method for producing same |
| 06/13/2001 | EP1105462A1 Engraftable human neural stem cells |